ID: ALA69234

Max Phase: Preclinical

Molecular Formula: C14H14N3O12PS2

Molecular Weight: 511.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1nc(/N=N/c2ccc(S(=O)(=O)O)cc2S(=O)(=O)O)c(COP(=O)(O)O)c(C=O)c1O

Standard InChI:  InChI=1S/C14H14N3O12PS2/c1-7-13(19)9(5-18)10(6-29-30(20,21)22)14(15-7)17-16-11-3-2-8(31(23,24)25)4-12(11)32(26,27)28/h2-5,19H,6H2,1H3,(H2,20,21,22)(H,23,24,25)(H,26,27,28)/b17-16+

Standard InChI Key:  PNFZSRRRZNXSMF-WUKNDPDISA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 511.38

Molecular Weight (Monoisotopic): 510.9757

AlogP: 1.43

#Rotatable Bonds: 8

Polar Surface Area: 250.41

Molecular Species: ACID

HBA: 11

HBD: 5

#RO5 Violations: 2

HBA (Lipinski): 15

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 2

CX Acidic pKa: -3.33

CX Basic pKa:

CX LogP: -3.28

CX LogD: -7.35

Aromatic Rings: 2

Heavy Atoms: 32

QED Weighted: 0.15

Np Likeness Score: -0.13

References

1. Jacobson KA, Kim YC, Wildman SS, Mohanram A, Harden TK, Boyer JL, King BF, Burnstock G..  (1998)  A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.,  41  (13): [PMID:9632352] [10.1021/jm980183o]

2. Kim YC, Brown SG, Harden TK, Boyer JL, Dubyak G, King BF, Burnstock G, Jacobson KA..  (2001)  Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.,  44  (3): [PMID:11462975] [10.1021/jm9904203]

3. Jacobson KA, Jarvis MF, Williams M..  (2002)  Purine and pyrimidine (P2) receptors as drug targets.,  45  (19): [PMID:12213051] [10.1021/jm020046y]

4. PubChem BioAssay data set, 

5. PubChem BioAssay data set, 

6. PubChem BioAssay data set, 

7. Cho JH, Jung KY, Jung Y, Kim MH, Ko H, Park CS, Kim YC..  (2013)  Design and synthesis of potent and selective P2X₃ receptor antagonists derived from PPADS as potential pain modulators.,  70  [PMID:24246730] [10.1016/j.ejmech.2013.10.026]

8. Lee SY, Müller CE..  (2017)  Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors.,  8  (5): [PMID:30108800] [10.1039/C7MD00015D]

9. Tian M, Abdelrahman A, Baqi Y, Fuentes E, Azazna D, Spanier C, Densborn S, Hinz S, Schmid R, Müller CE..  (2020)  Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists.,  63  (11): [PMID:32345019] [10.1021/acs.jmedchem.0c00435]

10. Mahmood A, Villinger A, Iqbal J..  (2022)  Therapeutic potentials and structure-activity relationship of 1,3-benzodioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors.,  238  [PMID:35660250] [10.1016/j.ejmech.2022.114491]

Source

Source(2):

• Scientific Literature
• PubChem BioAssays